• Program > The scientific symposium

    Scientific Symposium

  • Cancer, a World burden.
    Every year in the world, approximately 10 million people are diagnosed with cancer, and more than 6 million die from the consequences or relapses of this disease. Currently, worldwide, more than 22 million people are affected by cancer.
    Many evidences show that tumoral development is a multi step process involving genetic changes leading to the transformation of normal cells into tumoral cells. However, cancer development is not only due to these intrinsic changes but also involves the microenvironment, which plays a major role.
    The international symposium will benefit from the presence of two Nobel Prizes (Pr. Jules Hoffmann, Nobel Prize 2011 in Medicine and Pr. Gerd Binnig, Nobel Prize 1986 in Physics) and sixteen international experts in the field of oncology (researchers and clinicians). Moreover, thirty talks and one hundred poster presentations selected following the call for papers will be held.
    Six scientific sessions are proposed to present the recent studies realised in basic, translational and clinical research allowing an overview of new concepts and studies from the bench to the bed of patients.
    The focus will be put on:
    • Genetic instability and cell cycle
    • Gene expression and epigenetic
    • Metabolism
    • Tumoral biology and stem cells
    • Immunity
    • Health technology
  • Session : Immunity

    Benoit Van den Eynde

    Ludwig Institute for Cancer Research Ltd, Brussels, Belgium

    Benoît Van den Eynde, MD, PhD, is a tumor immunologist. He is director of the Brussels Branch of the Ludwig Institute for Cancer Research, co-director of the de Duve Institute, and Professor at the Université catholique de Louvain.  He initially identified, together with Thierry Boon, the first tumor rejection antigen naturally expressed by mouse tumors. He subsequently identified a number of human tumor antigens and studied their processing. This led to the discovery of peptide splicing by the proteasome and of novel proteasome subtypes.  He also described how tumors resist immune rejection by catabolizing tryptophan, through the expression of indoleamine dioxygenase or tryptophan dioxygenase.

    Session : Immunity

    Eric VIVIER

    Centre d’Immunologie de Marseille-Luminy, Marseille, France

    Eric Vivier is a Professor of Immunology at the Aix-Marseille University and Assistance Publique des Hôpitaux de Marseille, a co-founder of Innate-Pharma (innate-pharma.com) and is currently director of the Centre d’Immunologie de Marseille-Luminy (ciml.univ-mrs.fr) and the coordinator of Marseille-Immunopole (marseille-immunopole.org).

    His scientific interests are focused on investigating the functions of Innate Lymphoid Cells (ILCs) in humans and mice, their articulation with other components of the immune system, and their manipulation in the frame of innovative therapies against cancer and inflammatory disorders. He is a member of the Insitut Universitaire de France and of the French National Academy of Medicine.

    Session: Gene expression and epigenetics

    Professeur Eric Solary

    Institut Gustave Roussy Paris, FRANCE

    Eric Solary, 59 year-old, is MD, full-Professor in Haematology at Paris-Sud University, head of research in Gustave Roussy Comprehensive Cancer Center, and director of team 4 in Inserm Unit 1170 « Normal and pathological haematopoiesis ».

    He is teaching clinical and biological haematology as well as cell biology at Paris-Sud 11 faculty of Medicine. He is the former Scientific Director of the Canceropole Ile de France and the present President of the Scientific Committee of the Foundation ARC, a charity dedicated to cancer research funding.

    Eric Solary’s research has been dedicated initially to leukemic cell resistance to cytotoxic drugs, then cell death mechanisms and the link between cell death and differentiation in the hematopoietic system. His current research is focused on monocyte response to cytokines and chronic myeloid malignancies, especially chronic myelomonocytic leukemia

    Site internet :

    Session: Gene expression and epigenetics

    Mario Fdez. Fraga


    Currently, Mario Fdez. fraga leads the Cancer Epigenetic Laboratory at the Nanomaterials and Nanotechnology Research Centre (CINN-CSIC) and the Institute of Oncology of Asturias (IUOPA). He carried out his Ph.D. work at the University of Oviedo and, during this period he worked on the development of novel technologies to analyse genomic DNA methylation and on the study of epigenetic changes during development.

    From 2001 to 2005 he was a Postdoctoral Fellow at the Spanish National Cancer Centre (CNIO). He focused on the study of novel epigenetic alterations in cancer. Mario F.Fraga is currently interested in the study of epigenetic mechanisms involved in human development and their alterations in cancer. These include, among others, DNA methylation, histone modifications and the epigenetic enzymes driving these processes. His laboratory also aims to translate this knowledge into better clinical diagnosis and treatment of cancer patients.

    Mario F.Fraga is author of over one hundred sixty original peer-reviewed manuscripts and he is member of numerous International Scientific Societies, Editorial Boards and reviewer from various journals and funding agencies.


    Site internet :

    Session: Genetic instability and cell cycle

    Marcos Malumbres

    Centro Nacional de Investigaciones Oncológicas, SPAIN

    Marcos Malumbres is head of the Cell Division and Cancer group at the Spanish National Cancer Research Centre (CNIO). His research is focused to the understanding of the control of cell proliferation and its alteration in cancer cells. Among major regulators of this process, Dr. Malumbres is interested in the regulation of major cell cycle kinases and phosphatases as well as the proteolytic machinery. He is also interested in the control of cell proliferation by microRNAs and the differences in the regulation of the cell division cycle in different cell types, including pluripotent cells.

    Session: Genetic instability and cell cycle

    Óscar Fernández-Capetillo, PhD


    Óscar Fernández-Capetillo obtained his PhD from the Universidad del País Vasco working on the role of E2F transcription factors on the development of the immune system with A. Zubiaga.

    He then joined the laboratory of A. Nussenzweig at the National Cancer Institute, USA, where he started to work on the cellular response to DNA damage, focusing particularly on the role of the histone variant H2AX and other chromatin-related aspects.

    Since 2005, he leads the the Genomic Instability Group where his work has continued to focus on chromatin but now mainly concentrates on developing chemical, cellular and animal tools for studying the role of the ATR/Chk1 signalling cascade in the protection against cancer and ageing.

    Site internet :

    Session: Genetic instability and cell cycle

    Prof. Thomas Helleday

    Karolinska Institute, SWEDEN

    Thomas Helleday is the Torsten and Ragnar Söderberg Professor in Translational Medicine and Chemical Biology at Karolinska Institutet, SciLifeLab, and he heads a large interdisciplinary laboratory covering basic, translational and also clinical science. His discovery of PARP inhibitors in treatment of BRCA mutated cancers was approved by the FDA and EMA in 2014, and the treatment is today widely used in the clinic.

    The laboratory focuses on identifying novel drugs to DNA repair proteins essential in cancer and bringing these to patients within the academic setting, using open innovation. Thomas Helleday started a public foundation, the ‘Helleday Foundation’, owning intellectual property generated in the laboratory, with the aim to support long term drug development within the academic setting. Thomas Helleday has won numerous prestigious international prizes and is a fellow of the European Academy of Cancer Sciences and EMBO member.

    Site internet :

    Session: Health technologies

    Prof. Dr. Gerd Binnig

    Definiens AG, CTO and Founder, GERMANY

    Dr. Binnig studied at the J.W. Goethe University in Frankfurt, where he received his doctorate degree in 1978.  He then immediately joined IBM's Zurich Research Laboratory and stayed with IBM till 2002. During this time Dr. Binnig invented and developed the Scanning Tunneling Microscope, STM, together with his colleague Dr. Heinrich Rohrer. He went on to invent the Atomic Force Microscope, AFM, which he developed together with Calvin Quate and Christoph Gerber during a sabbatical at IBM Almaden Research Center (1985/86) and a guest professorship at Stanford University (1985-88). Additionally, he opened and headed a small IBM research group from 1987 to 1995 within the University of Munich, from which he received an honorary professorship.

    Through both techniques, STM and AFM, atoms on the surface of matter are imaged and manipulated so that features of single atoms, such as electronic states (STM) and interaction forces (AFM), can be measured. The potential of investigating and manipulating matter on the atomic scale started the new discipline of nanotechnology. In addition to receiving numerous awards and honors, Dr. Binnig was awarded the Nobel Prize in Physics together with his colleague Dr. Heinrich Rohrer for the invention of the STM.

    In 1995, Dr. Binnig together with the journalist Dieter Herold founded a small research group, which was the precursor of Definiens. In 2000 he founded the company Definiens by bringing in investors. With his team at Definiens he developed the Cognition Network Technology, CNT, to automatically understand complex data. This technique was initially applied to image analysis which uniquely enabled Definiens software to analyze large numbers of images automatically, just like the human eye and brain are capable of doing. Later, CNT was extended to the automated analysis of data tables derived from the analysis and rich quantification of tissue images, enabling the novel field of Tissue Phenomics®.

    Session: Heath technology

    Mickaël Tanter

    Research Professor of the French National Institute for Health and Medical Medical Research, Institute Langevin, ESPCI, Paris France

    Mickaël Tanter is the director of Inserm U979 laboratory “Wave Physics for Medicine” and deputy head of Langevin Institute, ESPCI, Paris, France. He is a world renowned expert in biomedical ultrasound and wave physics. He is the author of more than 200 peer-reviewed papers and the recipient of 35 patents. In 2006, he co-founded Supersonic Imagine, an innovative French company positioned in the field of medical ultrasound imaging and therapy, that launched in 2009 a revolutionary Ultrafast Ultrasound imaging platform called AixplorerTM with a unique real time shear wave imaging modality for cancer diagnosis (>140 employees, 152 M€ venture capital, and more than 1000 ultrafast scanners already sold worldwide). He received many national and international awards (among them the Honored Lecture of the Radiology Society of North America in 2012 and the Grand Prize of Medicine and Medical Research of Paris city). He was recently awarded a European Research Council (ERC) Advanced Grant to introduce fUltrasound imaging (functional imaging of brain activity) as a new full-fledged neuroimaging modality.


    Session: Metabolism


    Meyer Director, Sandra and Edward Meyer Cancer Center

    Professor of Cancer Biology in Medicine, Weill Cornell Medicine

    Lewis Cantley, Ph.D., has made significant advances in cancer research stemming from his discovery of the signaling pathway phosphoinositide 3-kinase (PI3K) in 1984. A graduate of West Virginia Wesleyan College (B.S., Chemistry, 1971) and Cornell University (Ph.D., Biophysical Chemistry, 1975), Dr. Cantley has been a professor at Tufts University and Harvard University. He served director of the Beth Israel Deaconess Cancer Center and is currently the Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. The author of more than 400 papers and 50 book chapters, Dr. Cantley has received several prestigious accolades, including membership in the American Academy of Arts and Sciences, the National Academy of Sciences and the Institute of Medicine of the National Academies.

    Session: Metabolism

    Professor V. Craig Jordan,

    OBE, PhD, DSc, FMedSci, USA

    Jordan is the Dallas/Ft. Worth Living Legend Chair of Cancer Research, Professor of Breast Medical Oncology, and Professor of Molecular and Cellular Oncology at the University of Texas MD Anderson Cancer Center, Houston, Texas. He is referred to as the “Father of Tamoxifen. Dr. Jordan also first described a new group of medicines called Selective ER Modulators (SERMs).He has received numerous awards including the American Cancer Society Medal of Honor, The Kettering Prize (General Motors Cancer Research Foundation), the Karnoffsky Award (ASCO), and the St. Gallen Prize for Clinical Breast Cancer Research (Switzerland). Her Majesty, Queen Elizabeth II, appointed hum Officer of the Most Excellent Order of the British Empire (OBE) for services to international breast cancer research. He is a member of the National Academy of Sciences, a Fellow of the AACR Academy, Honorary Fellow of the Royal Society of Medicine (UK), and a Fellow of the Academy of Medical Sciences. In 2014, Dr. Jordan was identified by ASCO as one of 50 Luminaries who have changed cancer care.

    Site internet :

    Session: Tumor biology and stem cell

    Dominik Rüttinger, M.D., Ph.D., F.A.C.S.

    Roche Innovation Center Penzberg, Germany

    Dr. Rüttinger completed residencies in Intensive Care and Surgical Oncology and is board certified in Surgery and Thoracic Surgery from the Ludwig-Maximilians-University of Munich (LMU), Germany. After fellowships within the Tumor Immunology Training Program at the Earle A. Chiles Research Institute, Providence Cancer Center, Oregon Health and Science University, Portland, USA and the Surgical Oncology Program at LMU, Dr. Rüttinger received his Ph.D. in Tumor Immunology at the University of Munich, where he still teaches and holds a faculty position.

    During his career in academia Dr. Rüttinger focused his translational research on cancer immunotherapy and served as principal investigator on multiple international Phase 1-3 clinical trials investigating active-specific immunotherapy and antibody-based approaches. He headed the Munich NSCLC Vaccine Study Group and served as advisor for the Gene Therapy Advisory Board UK (GTAC) and the Dutch Ministry of Health, Welfare and Sports. Dr. Rüttinger is also co-chairman of the German Society of Immunotherapy and Targeted Therapy (DGFIT). He served as ad hoc reviewer/board member for several oncology journals and has published more than 80 original articles and chapters.

    In 2007, Dr. Rüttinger joined Micromet Inc. (now Amgen Research), where he lastly served as Head Clinical Development Solid Tumor Oncology. The first T cell engaging BiTE® antibody blinatumomab (Blincyto™) was granted FDA approval in December 2014.

    Dr. Rüttinger joined Roche/Genentech in 2011 and has led multiple early clinical stage immunotherapy programs.

    Site internet :

    Session: Tumor biology and stem cell

    Mariano Barbacid, Ph.D.

    Centro Nacional de Investigaciones Oncologicas, SPAIN

    Mariano Barbacid got his Ph.D. in Madrid and trained as a postdoctoral fellow at the US National Cancer Institute. In 1978 he isolated the first human cancer gene (H-RAS) and identified first mutation associated with the development of human cancer. In 1988, he joined Bristol Myers-Squibb where he became Vice President, Oncology Drug Discovery. In 1998, he returned to his native Madrid to create and direct the Spanish National Cancer Research Center (CNIO).

    His work has been recognised by several awards including the Steiner Prize (Bern, 1988), Ipsen Prize (Paris, 1994), Brupbaher Cancer Research Prize (Zurich, 2005) and the Medal of Honour of the International Agency for Cancer Research (Lyon, 2007). In 2012, he was inducted to the National Academy of Sciences of the USA as a Foreign Member and in 2014 was elected Fellow of the AACR Academy. He also holds Honorary Degrees (Doctor Honoris causa) from the Universidad Internacional Menendez y Pelayo (1995), the University of Cantabria (2011) and the University of Barcelona (2014)..

  • According to France's Personal Data Privacy Act in effect since June 2004, you may send a request in writing to INSIGHT OUTSIDE 39 chemin du vieux chêne, 38240 Meylan / France, or by email webmaster@insight-outside.fr to access your file in order to consult, modify and/or delete your personal information.

    © 2005 - 2017 Insight Outside
    © Patrice Nin, Mairie de Toulouse

    39 chemin du vieux chêne
    38240 Meylan
    Tel : +33 825 595 525 (0,15€/min*)
    Fax : +33 4 38 38 18 19
    Information desk monday to friday from 2:00pm to 5:00pm

    (*) Prices starting from fixed line incumbent, a surcharge may be applied by operators, counting the second after the first 45 seconds.
    Centre de Congrès PIerre Baudis
    11 esplanade Complans Caffarelli
    31680 Toulouse